Navigation Links
Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease
Date:4/10/2008

NEW YORK, April 10 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), announced today that it has obtained a Notice of Allowance and completed the grant requirements to obtain a European patent relating to the Company's ANTISENILIN(R) antibodies and products being developed by the Company for the treatment of Alzheimer's disease. Grant of the European patent is expected in several weeks. Other patents related to the ANTISENILIN(R) antibodies have been granted in Japan, China and elsewhere. Patent applications are pending in the United States. Intellect Neurosciences is the exclusive assignee of the ANTISENILIN(R) patents, which are based on the invention of Dr. Daniel Chain, the Company's Chairman and CEO.

Dr. Chain commented: "The use of ANTISENILIN(R) monoclonal antibodies that specifically target the toxic forms of beta amyloid is at the forefront of the battle against Alzheimer's disease. In addition to the Company's products in development, our invention has been applied to promising drug candidates in clinical development by major pharmaceutical companies."

"Intellect's ANTISENILIN(R) antibody technology incorporates an important safety feature ("free-end specificity"), meaning that antibodies developed using the technology are designed to specifically block the neurotoxicity of beta amyloid, which accumulates in the brains of Alzheimer's patients. The blocking of the neurotoxicity is achieved by promoting clearance of beta amyloid away from sites of damage while minimizing the potential for adverse effects," explained Professor Donald Price, Professor of Pathology, Neurology and Neuroscience and Founding Director of the Alzheimer's Disease Research Center at The Johns Hopkins School of Medicine and a member of Intellect's Scientific Advisory Board. Professor Price added: "Dr. Chain's idea of using antibodies in this way to reduce amyloid toxicity in the brain has gained considerable momentum over the past
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
4. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
5. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
6. Amarin Secures Global Intellectual Property Rights for Lipid Programs
7. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
8. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
9. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
10. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
11. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Pittcon is pleased to announce ... Koichiro Matsuda, Horiba Scientific, have organized a session on ... JASIS , Asia’s largest analytical and scientific instruments ... Messe, Japan. , The four speakers in this ... Single Molecules to Single Cells” will present their use ...
(Date:8/29/2014)... California (PRWEB) August 29, 2014 ... of Energy's 2014 Hydrogen Production R&D Award ... -- by splitting water using sunlight. , Shared ... (NREL) and the University of Nevada, Las Vegas ... work developing models of photoelectrochemical solar-hydrogen production and ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... City, Ca. (PRWEB) August 28, 2014 ... E3 rating for an alcohol-based hand sanitizer, asks food ... harvest by comparing the hand sanitizer they’re currently using ... Spray . Hand hygiene is critical to fighting cross-contamination ... environment. Best Sanitizers believes there are key criteria ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Livermore Team Awarded for Hydrogen Production Research 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3
... - Companies that operate in the clean technology industry ... soon will have the opportunity to impress the 600 investors ... Capital Forum in San Francisco. , , Orion Energy ... Madison are among 20 emerging clean technology companies that will ...
... fellow travelers a thing or two about commuting. , ,The ... an executive-in-residence and one of its portfolio companies, Caden ... , Gregg Fergus And since Fergus has been ... his new posts reduce the distance between home and work. ...
... a judge for an industry award contest. It wasn't the Oscars. ... conference room at the Sheraton at Los Angeles International Airport ... of this year's Medical Design Excellence Awards (MDEA). , ... MDEA winners may very well save your life some day. , ...
Cached Biology Technology:Biotech executive books a career flight that's closer to home 2Biotech executive books a career flight that's closer to home 3And the winners in medical design are 2And the winners in medical design are 3And the winners in medical design are 4And the winners in medical design are 5And the winners in medical design are 6
(Date:8/29/2014)... USA - The rise of the Tibetan plateau -- ... -- is important for both its profound effect on ... study published in GSA Bulletin , Katharine Huntington ... isotope thermometry -- using modern and fossil snail shells ... in southwestern Tibet. , Views range widely on ...
(Date:8/28/2014)... bacterial culprits that may drive inflammatory bowel diseases (IBD) ... own intestinal immune responses as a guide. , The ... Cell . , Trillions of bacteria exist within the ... the development and progression of IBD. Yet it,s thought ... a person,s susceptibility to IBD and its potential severity. ...
(Date:8/28/2014)... neighbors than traditional cigarettes, but still release toxins ... from USC. , Scientists studying secondhand smoke from ... to harmful particles, with close-to-zero exposure to organic ... metals in second-hand e-cigarette smoke were found to ... high levels of polycyclic aromatic hydrocarbons cancer-causing ...
Breaking Biology News(10 mins):Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Yale study identifies possible bacterial drivers of IBD 2Second-hand e-cig smoke compared to regular cigarette smoke 2
... a common genetic disorder previously linked to lung disease ... lung cancer, according to a report in the May ... the JAMA/Archives journals. The disorder, alpha1-antitrypsin deficiency (1ATD), ... the U.S. population and especially those of European descent, ...
... NEW YORK (May 23, 2008) A study led ... Columbia University Medical Center/NewYork-Presbyterian and chairman of the Cardiovascular ... were administered the direct thrombin inhibitor bivalirudin during primary ... a lower rate of major bleeding, and a lower ...
... Institute of Pacific Islands Forestry have submitted a proposal ... of strawberry guava, a South American tree that has ... introduced in 1825 as a garden plant. The scientists ... Land and Natural Resources, and Hawai Department of Agriculture, ...
Cached Biology News:Genetic mutation associated with increased risk of lung cancer 2Findings released from 1 of the largest percutaneous coronary intervention trials ever 2Insect release proposed to control exotic strawberry guava 2
Request Info...
... the consumable measurement plate for ... individually controlled measurement sites. Each ... liquid flow channel system that ... solution and compound applications necessary ...
... application capable of dynamic scheduling, is designed ... lab automation workcells easy for lab personnel, ... programmers. • Users create methods ... you can build a flowchart, you can ...
... to grow, the need for greater detection ... necessary, especially when discerning very similar or ... Confocal Microscope System gives you a level ... available in conventional confocal systems, with detectors ...
Biology Products: